Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Small reprieve for German high-risk products, but is it enough?

This article was originally published in Clinica

Executive Summary

The latest chapter in the passage into law of Germany’s sickness insurance healthcare provision (GKV-VSG) draft is upon us. Today (11 June), the second and third readings were to be held (as agenda point 6) in the lower house. MPs were to hear draft law 18/4095 in its latest form, ie reflecting recent budget committee decisions and those of the 14th sitting of the health committee.

You may also be interested in...

Business As Usual For German Medtechs Amid Political Uncertainty, But EU Reg Cost Fears Mount

Germany has joined the unfortunate group of global economies coupled with the tag "political uncertainty." That much was assured when the government coalition talks in Berlin collapsed last week. Below the surface, life and business goes on as usual – and medtech is no different – but the vacuum can only last for so long.

EU Health Innovation Partnership Reflects Medtech’s Role In Unmet Needs

The EU Partnership on Health Innovation, a new public private health care research partnership, is in the final drafting phase before its launch under Horizon Europe. In Vivo asked the partnership’s medtech industry lead, Patrick Boisseau, to set out the innovation challenges for participants as they address unmet health care needs in Europe.

China’s NMPA Steps Up To The Plate In COVID-19 Fight But Much Is Left To Do

Chinese monitoring of the spread of COVID-19 locally has reported no new cases of home-grown infection in a single day for the first time since the outbreak began. It indicates control efforts, including the NMPA’s fast-tracking of relevant devices, PPE and IVDs, are having the desired effects.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts